Share:
Peer-Reviewed Publication
Function (Oxf)2025;6(4)August 1, 2025Journal Article

Sustained Accumulation of Molecular Clock Suppressors Period 1 and Period 2 Promotes C2C12 Myotube Atrophy Through an Autocrine-Mediated Mechanism With Relevance to Androgen Deprivation-Induced Limb Muscle Mass Loss.

Grant R Laskin1, Jennifer L Steiner1,2, Wayne A Ayers-Creech1, Michael L Rossetti1, Kirsten R Dunlap1, Cynthia Vied3, Choogon Lee4, Nicholas P Greene5, Dennis K Fix6, Orlando Laitano7, Kislay Parvatiyar1, Bradley S Gordon1,2
1Department of Health, Nutrition, and Food Sciences, Florida State University, Tallahassee, FL 32306, USA.
2Institute of Sports Sciences and Medicine, Florida State University, Tallahassee, FL 32306, USA.
3Translational Science Laboratory, Florida State University College of Medicine, Tallahassee, FL 32306, USA.
4Department of Biomedical Sciences, Florida State University College of Medicine, 115 W Call Street, Tallahassee, FL 32304, USA.
5Department of Health, Human Performance and Recreation, Cachexia Research Laboratory, Exercise Science Research Center, University of Arkansas, Fayetteville, AR 72701, USA.
6Recursion Pharmaceuticals, Salt Lake City, UT 84101, USA.
7Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL 32611, USA.

Abstract

Low testosterone in males (hypogonadism) is associated with limb muscle mass loss, yet the underlying mechanisms of muscle mass loss remain largely unknown. We previously showed androgen deprivation disrupted limb muscle molecular clock function, and the disruption coincided with elevated levels of the primary molecular clock suppressor, Period 2 (Per2). The purposes herein were to determine if PE…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.